Form 4: GeneDx Director Joshua Ruch Reports Routine Stock and RSU Transactions

GeneDx Holdings Corp. Director Joshua Ruch reported the acquisition of Class A Common Stock through RSU conversion and a new RSU grant, increasing his direct and indirect beneficial ownership.

Summary

• Joshua Ruch, a Director at GeneDx Holdings Corp. (WGS), reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs) on June 18, 2025.
• Mr. Ruch acquired 12,924 shares of Class A Common Stock through the conversion of derivative securities (RSUs) at a price of $0.
• He also received a grant of 3,576 new Restricted Stock Units (RSUs) at a price of $0.
• Following these transactions, Mr. Ruch directly beneficially owns 29,723 shares of Class A Common Stock.
• Additionally, he indirectly beneficially owns 14,845 shares through Kariba LLC, 30,138 shares through Rugu2 LLC, and 149,284 shares through VAAL Investment Partners Q9 LP.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement for no consideration.
• The RSUs are set to vest on the earlier of the next annual meeting of shareholders following the grant date or the first anniversary of the grant date, contingent on Mr. Ruch's continued service to the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director is increasing their stake (through RSU conversion) and receiving new equity compensation, aligning their interests with shareholders. However, it's a routine compensation event, not a significant open market purchase.

Positives

• A director, Joshua Ruch, increased his direct beneficial ownership of Class A Common Stock by 12,924 shares through the conversion of RSUs, indicating continued alignment with shareholder interests.
• The grant of 3,576 new Restricted Stock Units to a director suggests ongoing commitment and incentivization of key management personnel.

Future Outlook

The document indicates that newly granted Restricted Stock Units (RSUs) will vest on the earlier of the next annual meeting of the Issuer's shareholders following the grant date or the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive dynamics within the healthcare or diagnostics sector.

Stakeholder Impact

• Shareholders: The director's increased direct ownership and continued equity compensation align management interests with shareholder value, potentially signaling confidence in the company's future.

Next Steps

• The newly granted Restricted Stock Units (RSUs) are expected to vest on the earlier of the next annual meeting of GeneDx's shareholders following the grant date or the first anniversary of the grant date.

Key Dates

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Transaction, Joshua Ruch, Director, Restricted Stock Units, RSU, Class A Common Stock, Beneficial Ownership